AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18073554 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of smoked cannabis
Number of subjects: 15
Study 18073554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis exposure
Number of subjects: 15
Study 16188047 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation in Group A (severe atherosclerosis lesion of luminal narrowing >= 70%)
Number of subjects: 103
Study 16188047 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation in Group B (symptomatic myocardial bridge lesion of systolic luminal narrowing >= 95%)
Number of subjects: 103
Study 16188047 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation in Group C (severe atherosclerotic lesion of luminal narrowing >= 70%)
Number of subjects: 103
Study 16188047 — intervention group
Group type: COMPARATOR
Intervention: Comparison of restenosis rates among groups
Number of subjects: 103
Study 16188047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation at 20 months
Number of subjects: 103
Study 12351557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg/day
Number of subjects: 139
Study 12351557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 139
Study 12351557 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) 2 mg/day plus NETA 1 mg/day
Number of subjects: 139
Study 7728815 — intervention group
Group type: EXPERIMENTAL
Intervention: New adhesive resin system
Number of subjects: 0
Study 3140563 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 55
Study 3140563 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 55
Study 3140563 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil
Number of subjects: 55
Study 3140563 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 55
Study 3140563 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 55
Study 31476905 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 23964
Study 31476905 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 23964
Study 31476905 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 23964
Study 31476905 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 23964
Study 27296057 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-Vitamin D (1000 mg calcium + 5000 IU vitamin D3)
Number of subjects: 85
Study 27296057 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-alone (1000 mg)
Number of subjects: 85
Study 27296057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 25726845 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with IgAN
Number of subjects: 45
Study 25726845 — intervention group
Group type: COMPARATOR
Intervention: Younger adults with IgAN
Number of subjects: 45
Study 23905611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning labels (text-only and pictorial warnings)
Number of subjects: 2521
Study 22063371 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus aurantium blossom distillate 1mL.kg(‐1)
Number of subjects: 60
Study 22063371 — intervention group
Group type: COMPARATOR
Intervention: Saline solution 1mL.kg(‐1) as placebo
Number of subjects: 60
Study 19808137 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50-mg orally disintegrating tablet (ODT)
Number of subjects: 20
Study 19808137 — intervention group
Group type: COMPARATOR
Intervention: Conventional flurbiprofen 50-mg tablet
Number of subjects: 20
Study 19808137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study 17085137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tisseel vapor heated sealant) instilled under direct vision in the nephrostomy tract at the end of the procedure
Number of subjects: 63
Study 17085137 — intervention group
Group type: COMPARATOR
Intervention: Tubeless percutaneous nephrolithotomy without fibrin sealant
Number of subjects: 63
Study 15180934 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 0
Study 15180934 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis with novel constellations of metabolites
Number of subjects: 0
Study 11326372 — intervention group
Group type: EXPERIMENTAL
Intervention: Genioplasty with precise reattachment of the mentalis muscle
Number of subjects: 21
Study 11326372 — intervention group
Group type: COMPARATOR
Intervention: Genioplasty without precise reattachment of the mentalis muscle (control)
Number of subjects: 21
Study 9558411 — intervention group
Group type: EXPERIMENTAL
Intervention: IdCSA (1 mg/kg/d from day -1 to +20; n = 28)
Number of subjects: 60
Study 9558411 — intervention group
Group type: EXPERIMENTAL
Intervention: IdCSA + IdMTX (10 mg/m2 for day +1, 8 mg/m2 for days +3, +6, and +11; n = 32)
Number of subjects: 60
Study 9558411 — intervention group
Group type: COMPARATOR
Intervention: IdCSA
Number of subjects: 60
Study 9558411 — intervention group
Group type: COMPARATOR
Intervention: IdCSA + IdMTX
Number of subjects: 60
Study 9558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (>/= 29 years)
Number of subjects: 60
Study 9558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall for CR1 patients
Number of subjects: 60
Study 9558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with advanced disease
Number of subjects: 60
Study 9558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 60
Study 9522741 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 commonly prescribed syrup medications
Number of subjects: 60
Study 9522741 — intervention group
Group type: COMPARATOR
Intervention: 10% sucrose
Number of subjects: 60
Study 2574566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol hydrochloride
Number of subjects: 21
Study 2574566 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 21
Study 2574566 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21
Study 2574566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt test
Number of subjects: 21
Study 1091822 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (3.0 to 7.5 mg per day)
Number of subjects: 14
Study 1091822 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 14
Study 1091822 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin and Propranolol (given concurrently)
Number of subjects: 14
Study 1091822 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa or Propranolol (given in comparable doses)
Number of subjects: 14
Study 30668352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastiha (2.8 g/day)
Number of subjects: 68
Study 30668352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30668352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastiha
Number of subjects: 68
Study 27828878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong ART during pregnancy
Number of subjects: 200
Study 27828878 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of HIV status to primary partner
Number of subjects: 200
Study 25040636 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal education based on an Australian National Prescribing Service patient leaflet regarding antibiotics
Number of subjects: 34
Study 25040636 — intervention group
Group type: COMPARATOR
Intervention: No verbal education (Control group)
Number of subjects: 34
Study 22990037 — intervention group
Group type: EXPERIMENTAL
Intervention: Staggered release group (SR)
Number of subjects: 16
Study 22990037 — intervention group
Group type: COMPARATOR
Intervention: Standard release group (R)
Number of subjects: 16
Study 21331636 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliobond (HB)
Number of subjects: 80
Study 21331636 — intervention group
Group type: EXPERIMENTAL
Intervention: BisCover LV (BC)
Number of subjects: 80
Study 21331636 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Coat Plus (GP)
Number of subjects: 80
Study 21331636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasting Touch (LT)
Number of subjects: 80
Study 21331636 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Polishing (MP)
Number of subjects: 80
Study 21331636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 19288374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation
Number of subjects: 39
Study 19288374 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 39
Study 17488870 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-approach goals
Number of subjects: 0
Study 17488870 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-set performance-approach goals
Number of subjects: 0
Study 17488870 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative competence feedback
Number of subjects: 0
Study 15111525 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet(12h))
Number of subjects: 408
Study 15111525 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet(morn+bed))
Number of subjects: 408
Study 15111525 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (pooled)
Number of subjects: 408
Study 15111525 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 408
Study 11585854 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 35
Study 11585854 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study 9589700 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg daily) for 6 months
Number of subjects: 135
Study 9589700 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 78)
Number of subjects: 135
Study 8051377 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylactic treatment including cephapirine, gentamicin and metronidazole
Number of subjects: 269
Study 8051377 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 269
Study 2522716 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (titrated to partial thromboplastin time 1.5 to 2.5 times normal) administered for 18 to 24 hours
Number of subjects: 416
Study 2522716 — intervention group
Group type: COMPARATOR
Intervention: Dextrose administered for 18 to 24 hours
Number of subjects: 416
Study 2522716 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 416
Study 2522716 — intervention group
Group type: COMPARATOR
Intervention: Dextrose
Number of subjects: 416
Study 30022377 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education via patient education booklet
Number of subjects: 60
Study 30022377 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical nursing information
Number of subjects: 60
Study 28484316 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25 percent bupivacaine + 5 mg morphine (0.5 mL) infiltrated in Group P
Number of subjects: 130
Study 28484316 — intervention group
Group type: COMPARATOR
Intervention: None (Control Group C)
Number of subjects: 130
Study 25271729 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-guided individualized dosing of pazopanib
Number of subjects: 13
Study 25271729 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing of pazopanib (800 mg once daily)
Number of subjects: 13
Study 25271729 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Ctrough and C24 measurements
Number of subjects: 13
Study 25271729 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib AUC0‐24h
Number of subjects: 13
Study 23782907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-focused intervention
Number of subjects: 0
Study 23782907 — intervention group
Group type: COMPARATOR
Intervention: Healthy living intervention
Number of subjects: 0
Study 21495025 — intervention group
Group type: EXPERIMENTAL
Intervention: Workbook plus 3 in-person sessions with a trained peer counselor
Number of subjects: 300
Study 21495025 — intervention group
Group type: COMPARATOR
Intervention: Workbook plus ≤ 30 minutes of telephone counseling
Number of subjects: 300
Study 18949545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (32 mg/day for 6 weeks)
Number of subjects: 0
Study 18949545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16582114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime sexual partners
Number of subjects: 165
Study 16582114 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent sexual intercourse during early pregnancy
Number of subjects: 165
Study 14517513 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterally dosed recombinant human erythropoietin (rEpo) 1000 U/kg per day
Number of subjects: 36
Study 14517513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11125766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity
Number of subjects: 15
Study 11125766 — intervention group
Group type: COMPARATOR
Intervention: No sexual activity (control)
Number of subjects: 15
Study 9201803 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (cumulative doses of 0.05, 0.10, 0.25, 0.50 and 1.00 mg at 15-min intervals)
Number of subjects: 20
Study 9201803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1283061 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated, oral, double-blind, placebo-controlled challenge (DBPCFC) with fresh egg or milk
Number of subjects: 19
Study 1283061 — intervention group
Group type: COMPARATOR
Intervention: RAST test
Number of subjects: 19
Study 1283061 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 19
Study 1283061 — intervention group
Group type: COMPARATOR
Intervention: Histamine release test
Number of subjects: 19
Study 3516953 — intervention group
Group type: EXPERIMENTAL
Intervention: MFD (3 X 1.6 Gy/day for 10 days, 3 weeks rest, followed by a boost to 67.2 or 72 Gy) + Misonidazole (1 g/m2 every irradiation day, total 12 to 14 g/m2)
Number of subjects: 523
Study 3516953 — intervention group
Group type: EXPERIMENTAL
Intervention: MFD (3 X 1.6 Gy/day for 10 days, 3 weeks rest, followed by a boost to 67.2 or 72 Gy)
Number of subjects: 523
Study 3516953 — intervention group
Group type: COMPARATOR
Intervention: Classical radiotherapy 70 Gy/7 weeks
Number of subjects: 523
Study 31338989 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (measured through genetic risk score and SNPs)
Number of subjects: 156701
Study 28949011 — intervention group
Group type: EXPERIMENTAL
Intervention: CWARTS diagnostic tool
Number of subjects: 299
Study 26987980 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day oral diclofenac
Number of subjects: 99
Study 26987980 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg methylprednisolone injection
Number of subjects: 99
Study 26987980 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (diclofenac + methylprednisolone)
Number of subjects: 99
Study 24803131 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory gating module (AccuResp algorithm, Carto3, Biosense Webster) enabled
Number of subjects: 140
Study 22572215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (defined by a Nugent score ≥ 7)
Number of subjects: 14193
Study 22572215 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking during pregnancy
Number of subjects: 14193
Study 22572215 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age 18‐19 years
Number of subjects: 14193
Study 22572215 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level (completed only primary school)
Number of subjects: 14193
Study 22572215 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level (completed only secondary school)
Number of subjects: 14193
Study 22572215 — intervention group
Group type: EXPERIMENTAL
Intervention: History of preterm delivery
Number of subjects: 14193
Study 20206528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vibrotactile, auditory and visual biofeedback of angular trunk displacement during training on balance tasks
Number of subjects: 64
Study 20206528 — intervention group
Group type: COMPARATOR
Intervention: Balance training without real‐time biofeedback
Number of subjects: 64
Study 17460970 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethasidine MB (70 mg daily)
Number of subjects: 65
Study 17460970 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐TMHP (1000 mg daily)
Number of subjects: 65
Study 17460970 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic therapy with ACE inhibitors, beta-blockers, and diuretics)
Number of subjects: 65
Study 15070820 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma patients
Number of subjects: 0
Study 15070820 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects without asthma
Number of subjects: 0
Study 12165185 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) interventions
Number of subjects: 0
Study 12165185 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research methods
Number of subjects: 0
Study 9807986 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 300-350 mg/m2 infused once every 3 weeks
Number of subjects: 267
Study 9807986 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil by continuous infusion
Number of subjects: 267
Study 9807986 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 267
Study 9807986 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil
Number of subjects: 267
Study 9807986 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 267
Study 7700731 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 8
Study 7700731 — intervention group
Group type: COMPARATOR
Intervention: Control group (47 infants without pulmonary disease)
Number of subjects: 8
Study 2375671 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized scanning and attentional training (mean of 15.5 hours, SD = 1.8)
Number of subjects: 36
Study 2375671 — intervention group
Group type: COMPARATOR
Intervention: Recreational computing (mean of 11.4 hours, SD = 5.2)
Number of subjects: 36
Study 100029 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin, isoniazid, and rifampin given daily for 6 months
Number of subjects: 680
Study 100029 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin, isoniazid, rifampin, and pyrazinamide given daily for 2 months, followed by twice-weekly administration of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 680
Study 100029 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin, isoniazid, rifampin, and ethambutol given for 6 or 8 months
Number of subjects: 680
Study 100029 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin, isoniazid, rifampin, and pyrazinamide given 3 times per week for 4 months, followed by streptomycin, isoniazid, and pyrazinamide administered twice per week
Number of subjects: 680
Study 31884852 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal BP with higher levels of physical activity
Number of subjects: 3078
Study 31884852 — intervention group
Group type: EXPERIMENTAL
Intervention: Light activity in persons with LVH
Number of subjects: 3078
Study 31884852 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/high activity in persons with LVH
Number of subjects: 3078
Study 31884852 — intervention group
Group type: COMPARATOR
Intervention: Hypertension with higher levels of physical activity
Number of subjects: 3078
Study 30204735 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based video instruction (CBVI)
Number of subjects: 29
Study 30204735 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 28067198 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable polymer PtCr‐EES
Number of subjects: 11036
Study 28067198 — intervention group
Group type: COMPARATOR
Intervention: Other new‐generation DES
Number of subjects: 11036
Study 26454228 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconceptional micronutrient supplements
Number of subjects: 1436
Study 26454228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG)
Number of subjects: 1436
Study 26454228 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy weight <43 kg
Number of subjects: 1436
Study 26454228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain <8 kg
Number of subjects: 1436
Study 23506690 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional herbal medicine (THM) regimen including Cinobufacini injection and Jiedu Granule
Number of subjects: 379
Study 23506690 — intervention group
Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 379
Study 21110096 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 24
Study 21110096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 24
Study 19118820 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate 20-minute bicycle exercise at approximately 65% to 70% VO(2peak)
Number of subjects: 38
Study 16398593 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 524
Study 16398593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 11815577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin MR 500 mg once daily for 5 days
Number of subjects: 349
Study 11815577 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 590 mg three times daily for 10 days
Number of subjects: 349
Study 11815577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin MR
Number of subjects: 349
Study 11815577 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 349
Study 10037121 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated RBCs
Number of subjects: 16
Study 10037121 — intervention group
Group type: COMPARATOR
Intervention: Control RBCs
Number of subjects: 16
Study 7735025 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention (n = 57)
Number of subjects: 122
Study 7735025 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (control, n = 65)
Number of subjects: 122